Disease-specific mortality rates for men with prostate cancer are comparable for 3 treatment options: active surveillance, radical prostatectomy, and external-beam radiotherapy.
Despite that most patients with newly diagnosed prostate cancer receive high-quality care, a racial disparity exists, a recent study has shown.
The long-term use of androgen deprivation therapy (ADT) for up to 36 months does not appear to be associated with cognitive decline in patients with prostate cancer.
Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.
Emotional distress is associated with an increased likelihood of opting for surgery among men with localized prostate cancer.
Race is not associated with the development of metastases in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to a recently published study.
Ethnicity influences patient decision to pursue active treatment and serial biopsies in active surveillance
Use of androgen suppression therapy may negatively impact survival in African American patients with favorable-risk prostate cancer.
Despite previous research demonstrating that the use of PDE-5 inhibitors such as sildenafil, tadalafil, and vardenafil may reduce the risk for developing prostate cancer, a new study suggests that these agents do not prevent prostate cancer.
As salvage radiotherapy (SRT) outcomes may be affected by factors associated with prostatectomy findings, they may be positively affected when used at lower prostate-specific antigen (PSA) levels.
Choosing no treatment and regular check-ups didn't seem to stress men with low-risk disease
Using an online decision-support tool led to most men with low-risk prostate cancer choosing active surveillance with less conflict about their decision.
Researchers in Sweden have, for the first time, estimated the risk of developing various types of prostate cancer for men with brothers and/or fathers with the disease.
Analysis of proteins identified in urine has led to the discovery of proteomic signatures for prostate cancer that have the potential to serve as highly accurate noninvasive biomarkers that can identify aggressive disease before surgery.
Functional status, a person's ability to perform normal activities of daily living, is associated with treatment choice for patients with prostate cancer.
Consumption of tree nuts is associated with lower mortality rates among men with prostate cancer. It did not, however, correlate with a reduced risk of developing prostate cancer.
Prostate-specific molecular imaging at initial biopsy and preoperative planning can accurately determine and delineate the extent of prostate cancer. The imaging technique was a type of PET/CT called 68Ga-PSMA PET/CT.
Laser heat may soon be an option to treat prostate cancer. Focal laser ablation has been found both feasible and safe in men with intermediate risk prostate cancer.
Screening PSA levels at midlife could identify men who are at greater risk of developing prostate cancer later in life and who should be monitored more closely.
Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.
PSA levels in midlife strongly predict future lethal prostate cancer risk in U.S. cohort.
Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.
Length of stay (LOS) and blood loss were reduced with RARP compared with open radical prostatectomy in obese men with prostate cancer who underwent surgery for their disease.
Radiation therapy delivered to the critical vessels surrounding the prostate can result in erectile dysfunction and bladder and renal irritation. Vessel-sparing radiation and an improved understanding of the anatomy of the prostate can reduce these effects.
New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.
Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer
Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.
Radiotherapy in combination with anti-androgen hormone therapy halves the risk of death from prostate cancer 15 years after diagnosis compared with hormone therapy alone.
The second-generation hsp90 inhibitor onalespib may be beneficial for men with prostate cancer that no longer responds to androgen deprivation therapy
Research also suggests that statins may help counteract harmful effect of fatty foods
A moderate to high level of physical activity before and after diagnosis may improve prognosis in patients with non-metastatic prostate cancer.
Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer
Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.
A new urine assay that can detect genetic changes correlated with prostate cancer correctly identified cancer grade in 92% of men with elevated PSA levels and high-grade cancers.
Researchers found that men with prostate cancer who had exercised regularly had the best outcomes.
New technology has enabled doctors to administer higher doses of radiation to prostate cancer tumors with fewer side effects; however, escalating the dose of radiation may not help patients with localized prostate cancer in the long term.
Site of metastasis is key to the length of time a patient can survive metastatic castration-resistant prostate cancer (mCRPC).
Men age 67 years or older with prostate cancer were 37% more likely to be hospitalized for noncancer reasons after their cancer diagnosis than before their diagnosis.
Radiation doses to the bladder and rectum were reduced with intensity-modulated radiotherapy (IMRT) for prostate cancer.
Higher Treatment Volumes at Radiation Facilities Lead to Improved Overall Survival in Prostate Cancer
Among men with aggressive prostate cancer, overall survival (OS) rates improve when they receive radiation treatment at facilities that frequently perform the treatment.
The combination of bicalutamide and everolimus may be effective in men with bicalutamide-naïve castration-resistant prostate cancer (CRPC).
A complex surgical procedure to remove the prostate achieves excellent long-term survival for men with prostate cancer after radiation therapy has failed.
Although reported absolute rates of second malignancies after radiotherapy for prostate cancer are very low, it is associated with higher rates of bladder, colon, and rectal cancers in patients who undergo radiotherapy for prostate cancer.
Both insufficiency and deficiency of serum vitamin D correlated with an increased risk of unfavorable pathology in men undergoing radical prostatectomy for prostate cancer.
Patients with slow-growing prostate cancer are increasingly opting for active surveillance and only changing treatment plan if the disease changes to a higher risk form to avoid unnecessary and potentially toxic treatments.
Adding 6 months of adjuvant androgen suppression to radiotherapy improves biochemical and clinical disease-free survival (DFS).
The use of proton therapy to treat patients with prostate cancer increased more than 2-fold from 2004 to 2012.
Overall survival (OS) is worse for men with castration-resistant prostate cancer (CRPC) metastases to the lung and liver.
Very few older man receive the intensity of active surveillance testing recommended by major prospective active surveillance (AS) programs.
Recent developments in a gas chromatography tool might allow doctors to determine whether urologic cancers are present via a urine sample.
The risk for developing colorectal cancer is increased after a diagnosis of prostate cancer.
Radium-223 dichloride (radium-223) improves overall survival in patients with castration-resistant prostate cancer (CRPC).
Survivors of prostate cancer should be made aware of an increased risk for heart disease. It is the most common noncancer cause of death for men with prostate cancer.
The growth of castration-resistant prostate cancer cells was reduced by a first-in-class sphingosine kinase 2 inhibitor, but the cells were not killed.
Men with prostate cancer and bone metastases that have experienced at least one skeletal-related event (SRE) show worse survival, according to a recent study.
Positron emission tomography (PET) imaging may offer a superior method of imaging for metastatic prostate cancer.
This fact sheet reviews the PSA test for prostate cancer, in particular screening recommendations, test limitations, and possible improvements the future may hold in store for the test.
Among persons 65 years or older with limited life expectancies of less than 10 years, an estimated 15.7% may have undergone nonrecommended screenings for prostate and breast cancers.
Enzalutamide significantly reduced the risk of prostate cancer progression or death in prostate cancer.
Phase 3 results of the TRAPEZE trial of patients with bony metastatic castrate-refractory prostate cancer (CRPC).
The risk of lethal prostate cancer, but not of overall, high-grade, or advanced cancers, was reduced with regular aspirin use.
Novel Diagnostic Test Uses CTCs in Blood to Guide Treatment Decisions for Patients With Prostate Cancer
An experimental liquid biopsy using a blood sample may determine which patients with prostate cancer will benefit from hormone therapies.
Important discussions about prostate cancer screening and treatment are not occurring between men and their health care team.
A total of 40% of patients with mCRPC treated with docetaxel after abiraterone achieved at least a 50% reduction in PSA, according to a study presented at the 2016 Genitourinary Cancers Symposium.
African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.
Risks of Adverse Effects Lower With Surgical Castration Vs. Chemical Castration for Metastatic Prostate Cancer
Surgical castration via orchiectomy for metastatic prostate cancer is associated with lower risks for adverse effects compared with medical castration via GnRHa therapy.
Twins carry a significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a long-term follow-up study of twins in Nordic countries.
Gonadotropin-releasing hormone agonist (GnRHa) therapy is associated with increased risks of numerous clinically relevant adverse events compared with orchiectomy.
A study compared the number of adverse events caused by both intermittent and continuous androgen-deprivation therapy (ADT) for prostate cancer.
Patients with prostate cancer who have undergone radical prostatectomy have largely unrealistic expectations with respect to their postoperative sexual function.
Docetaxel should be added at initiation of standard of care treatment in men with prostate cancer; however, no evidence of survival improvement was seen with zoledronic acid therefore it is not recommended as part of standard of care for this patient population.
Tumor Location and Duration of Therapy Influence Palliative Effects of Radiation Therapy for Painful Bone Metastases
In a review of the Dutch Bone Metastasis Study results, stratified for primary tumor location, palliative radiation therapy was found to reduce pain and improve quality of life for some patients.
Repeating PSA Test in Select Patients Can Mitigate Controversial Issues in Prostate Cancer Screening
Some task forces advocate abandoning the use of the screening PSA test because it leads to unnecessary prostate biopsies. Canadian researchers show that repeating the test in select patients can reduce the number of biopsies.
Economic burden is significantly higher for survivors of colorectal, breast, and prostate cancers compared with persons with no cancer history; however, excess economic burden attributable to cancer varies by cancer site and age.
In a study that demonstrates the emerging technique of extracting biomedical data from ordinary patient medical records, a nearly 2-fold increase was seen in the rate of Alzheimer disease diagnoses among men with prostate cancer who received ADT.
Men with prostate cancer are at risk for brittle bones as an adverse effect of their treatment; however, 1 hour of soccer training a few times a week counters many of the negative effects of treatment.
A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed.
A study that tracked tens of thousands of midlife and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may reduce their chances of developing a lethal type of prostate cancer by up to 68%.
Men undergoing active surveillance for low-risk prostate cancer may not be receiving proper monitoring.
The impact on PSA screening and prostate cancer incidence before and after the 2012 USPSTF screening recommendations were examined in two recent studies.
A small study shows those undergoing radiation therapy had fewer side effects and less fatigue when practicing yoga.
A new test is better at detecting aggressive prostate cancer than measuring PSA levels. The new test discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies.
Blood Test Identifies Mutations Behind Drug Resistance in Patients Taking Antiandrogen for Prostate Cancer
Scientists developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug and which patients will not respond to the treatment in advance.
Patients who are undergoing radiotherapy for prostate cancer may benefit from yoga.
Both the incidence of early stage prostate cancer and rates of prostate-specific antigen (PSA) screening oincide with the 2012 USPSTF recommendation.
Androgen deprivation therapy is associated with declines in self-reported physical functioning and upper body muscle strength.
The cost of treatment for low-risk prostate cancer varies widely. A new study examined the cost of care from when a patient checks in for his first appointment through his posttreatment follow-up testing via the use of time-driven activity-based costing.
For veterans with early-stage prostate cancer, patient age and tumor risk were found to be more strongly associated with use of expectant management.
Older black men with localized prostate cancer were more likely to have poorer quality care, incur higher costs, and have worse postoperative outcomes than white men. However, that did not translate to worse overall or cancer-specific survival.
Overall survival in men with rising PSA levels after prostatectomy for prostate cancer was statistically improved by adding a 24-month course of AAT during and after salvage radiotherapy, compared with salvage radiotherapy alone.
Clinical trial results confirm that newly diagnosed early stage prostate cancer can be treated with hypofractionated radiotherapy and experience the same level of cancer control as those treated with conventional radiotherapy.
A high response rate was seen among patients whose metastatic castration-resistant prostate cancers had DNA-repair defects.
Scientists have gained a key insight into how prostate tumors get their start. Instead of rewriting the normal DNA code, the master regulator of genes in prostate cells is reprogrammed to drive malignant growth.
Black patients treated with radical prostatectomy for localized prostate cancer (PCa) are more likely to experience adverse events.
No reduction in risk of distant metastasis, cancer-related deaths, radiation-linked adverse effects were connected to the use of men's health supplements (MHSs).
Use of testosterone therapy has increased in the last decade and the potential long-term risks associated with this therapy have been of concern.
Researchers identified two new cancer-causing gene mutations that could lead to more targeted and effective treatments for certain lung and prostate cancers.
In the study, management was changed in 44% more cases by Use of the imaging agent Ga-68 PSMA with PET/CT resulted in a change in management of prostate cancer in 44% more cases than with another widely used agent.
Evidence suggests that androgen deprivation therapy is associated with nonfatal cardiovascular events.
A recent study examined the potential benefits and potential downsides to the USPSTF recommendation against regular PSA screening.
Electronic triggers designed to search for key data were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer.
A molecular imaging biomarker is able to detect fast-growing primary prostate cancer.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
- Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Affordable Care Act Tied to Increased Breast Cancer Care Access for Hispanics
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|